Mark Treherne

Mark Treherne is a board member at the Biotechnology Business Institute. Mark has also served as chief executive for Cellesce Ltd, NuVision Biotherapies Ltd, and Avilex Pharma ApS.

Treherne has over 25 years of experience in the biotechnology industry. Mark co-founded Cell Guidance Systems in 1996, which developed technology to enable the growth and expansion of organoids. In 2016, they co-founded Avilex Pharma ApS, which is a spin out from the University of Copenhagen. AVLX-144, a drug developed by Avilex Pharma, is currently in clinical trials.

Treherne has a wealth of experience in developing and commercializing new technologies in the biotechnology industry. Mark has played a pivotal role in the growth and success of multiple companies, and their work has helped to advance cancer research and drug discovery.

Mark Treherne has a Ph.D. in Pharmacology from the University of Cambridge, an M.Phil. in Pharmacology from the University of Cambridge, and a B.Sc. in Physiology and Pharmacology from the University of St Andrews.